A federal jury has ordered Medtronic to pay $88 million to an Alabama couple after finding that the company's Covidien unit failed to adequately warn physicians about risks associated with its Symbotex hernia mesh.
The verdict came on August 4 following a three-week trial before U.S. District Judge Patti B. Saris in the U.S. District Court for the District of Massachusetts in Boston, where the federal hernia mesh litigation is consolidated. Larry Patterson, 61, received the implant during a 2017 surgery. The jury awarded $77 million to Patterson and $11 million to his wife, Tammy Patterson, on her loss of consortium claim.
The distinction that matters for patients is narrow but real. Jurors did not find that hernia mesh is defective or unsafe for everyone who receives it. They found that the warnings accompanying this specific product did not tell surgeons what they needed to know.
The Claim Centered on a Coating, Not the Mesh Itself
Symbotex is a composite device made of a permanent polyester textile covered by an absorbable collagen barrier derived from pig tissue. The coating is meant to temporarily keep the mesh from adhering to bowel and other organs while the patient's own tissue grows over the implant.
Patterson's attorneys argued that the porcine collagen coating dissolved sooner than physicians were led to expect, leaving the polyester exposed before healing was complete. According to the complaint and trial arguments, the mesh adhered to Patterson's bowel, causing an obstruction and a recurrent hernia, and he required a further operation in 2020.
Central to the failure-to-warn claim was the argument that the company had shifted from bovine to porcine collagen and knew the pig-derived coating would not last as long, without communicating that to implanting surgeons. The Minnesota Star Tribune reported that Patterson's lawyers presented testimony from Covidien scientists acknowledging the coating breaks down within seven days, while the lawsuit alleged the company trained its marketing team to tell physicians the coating lasted a month.
The jury found Covidien liable for failing to warn and also found that the company concealed important product information that caused injury. Jurors awarded no punitive damages. The entire award was compensatory. Covidien denied the allegations throughout, arguing that Patterson's medical history and other risk factors caused his injuries.
Failure to Warn Is a Narrower Finding Than Product Defect
In medical device litigation, a failure-to-warn verdict answers a specific question: did the manufacturer give physicians adequate information about known risks so they could make an informed decision and counsel the patient?
That is different from a finding that a device is defectively designed, and different again from a conclusion that a category of device should not be used. A product can be appropriate for many patients and still carry an inadequate warning label. Under the learned intermediary doctrine applied in most states, the duty to warn runs to the physician rather than directly to the patient, which is why the trial focused on what surgeons were told.
The verdict is also legally limited. It resolves one case. It does not bind other juries, does not establish liability in the thousands of remaining lawsuits, and does not compel any regulatory action.
Medtronic said it will challenge the verdict in post-trial motions and on appeal, calling the award excessive. In a statement, the company said it remains confident in the products, noting they have been used in millions of patients over two decades and that "hernia mesh has long been the standard of care" for repair of all but the smallest hernia defects. Plaintiffs' counsel described the award as the largest compensatory damages award in the history of mesh product litigation in the United States.
The Scale of the Litigation Behind This One Case
Patterson's case was the first bellwether, or test case, to go before a jury out of the federal Covidien hernia mesh litigation, formally multidistrict litigation No. 3029. Bellwether trials are used to give both sides information about how juries respond to evidence that will recur across many claims.
More than 2,400 Covidien hernia mesh lawsuits are pending in the consolidated federal proceeding. Reuters reported that roughly 10,350 plaintiffs nationally are pursuing claims against Medtronic involving several products, including Parietex, ProGrip and Symbotex, and Medtronic has told investors it faces more than 10,000 similar claims across federal and state courts. The figures describe different things: the federal consolidated docket versus total claims nationwide, rather than a contradiction.
This is now the last major body of hernia mesh litigation still active, after units of Becton Dickinson and Johnson & Johnson largely resolved claims against them.
Guidance for Patients Who Already Have Mesh
Hernia repair with mesh remains a standard surgical approach, and the verdict does not change clinical guidance. Roughly a million hernia repairs are performed annually in the United States, and mesh reduces recurrence compared with suture-only repair for most defects.
Nobody should have a functioning implant removed because of a jury verdict. Explant surgery carries its own substantial risks, and most people with mesh never develop a complication.
Reasonable steps are more modest. Patients who had a hernia repair can ask their surgeon or the operating hospital which device was implanted and request that information in writing, since implant records are not always easy to retrieve years later. The FDA maintains public databases that allow anyone to look up a device identifier, and its medical device recall notices are searchable. Symptoms that warrant prompt evaluation after any hernia repair include increasing or persistent abdominal pain, a new bulge at the repair site, nausea and vomiting, inability to pass stool or gas, fever, or redness and drainage at the incision. Bowel obstruction symptoms require emergency care rather than a scheduled appointment.
Anyone considering legal options should consult an attorney rather than acting on news coverage, and no one should stop or change prescribed treatment based on a verdict.
The immediate next steps are Medtronic's post-trial motions before the trial judge and, if those fail, an appeal. Additional bellwether trials are expected to follow, and their outcomes will shape whether the litigation moves toward settlement. Whether the FDA takes any action regarding Symbotex labeling has not been announced. MedicalDaily will report on subsequent trials and any regulatory response.
Key Questions Answered
What did the jury actually decide? Jurors found that Medtronic's Covidien unit failed to give physicians an adequate warning about risks of its Symbotex hernia mesh and concealed important product information that caused injury. They awarded $88 million in compensatory damages and declined to award punitive damages.
Does this mean hernia mesh is unsafe? No. A failure-to-warn finding addresses the adequacy of the information given to surgeons, not whether the device is defective for all patients. Mesh remains the standard approach for repairing most hernia defects.
Should someone with hernia mesh have it removed? No one should seek removal because of a verdict. Explant surgery carries real risks and most patients never experience a complication. Concerns should be discussed with the operating surgeon.
How can a patient find out which device they received? Ask the operating surgeon or hospital for the implant record in writing. The FDA also maintains public databases allowing anyone to look up a device identifier, and its recall notices are searchable.
What symptoms warrant medical attention after hernia repair? Persistent or worsening abdominal pain, a new bulge at the repair site, fever, or redness and drainage at the incision should be evaluated. Vomiting with inability to pass stool or gas suggests possible obstruction and requires emergency care.
Is this verdict binding on other cases? No. It resolves one case and does not determine outcomes in the thousands of other pending claims, though bellwether results often influence settlement negotiations.
What happens next? Medtronic has said it will seek to overturn the award through post-trial motions and appeal. Additional bellwether trials are expected in the consolidated federal litigation.
